Skip to main content
Positive Results from Long-Term Treatment Studies for Vatiquinone Friedreich Ataxia Program
Main Menu
Search:
Submit
About PTC
Back
History
Leadership
Our Responsibility
Global Compliance Program
Locations
Our Science
Back
Splicing
Ferroptosis & Inflammation
Our Products & Pipeline
Therapeutic Areas
Back
Metabolism
Back
Familial chylomicronemia syndrome (FCS)
Familial partial lipodystrophy (FPL)
Phenylketonuria (PKU)
Neurology
Back
Amyotrophic lateral sclerosis (ALS)
Aromatic l-amino acid decarboxylase (AADC) deficiency
Duchenne muscular dystrophy (DMD)
Friedreich ataxia (FA)
Hereditary Transthyretin Amyloidosis (hATTR)
Huntington's Disease (HD)
Spinal muscular atrophy (SMA)
Careers
United States
Back
Start of Column
Americas
United States
Asia
Japan
Start of Column
Europe
Austria
Germany
Ireland
Italy
Spain
Sweden (EN)
Sweden
Switzerland
United Kingdom
Investors
Healthcare Providers
Patients & Caregivers
Search:
Submit
United States
Start of Column
Americas
United States
Asia
Japan
Start of Column
Europe
Austria
Germany
Ireland
Italy
Spain
Sweden (EN)
Sweden
Switzerland
United Kingdom
Investors
Healthcare Providers
Patients & Caregivers